XNASMRNA
Market cap12bUSD
Feb 07, Last price
32.60USD
1D
-3.01%
1Q
-30.39%
IPO
73.40%
Name
Moderna Inc
Chart & Performance
P/E
—
P/S
1.83
EPS
—
Div Yield, %
—
Shrs. gr., 5y
36.33%
Rev. gr., 5y
123.60%
Revenues
6.85b
-64.45%
Net income
-4.71b
L
CFO
-3.12b
L
Earnings
Feb 20, 2025
Profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 6,848,000 -64.45% | 19,263,000 8.61% | ||||||
Cost of revenue | 11,087,000 | 9,843,000 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (4,239,000) | 9,420,000 | ||||||
NOPBT Margin | 48.90% | |||||||
Operating Taxes | 772,000 | 1,213,000 | ||||||
Tax Rate | 12.88% | |||||||
NOPAT | (5,011,000) | 8,207,000 | ||||||
Net income | (4,714,000) -156.37% | 8,362,000 -31.47% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (1,107,000) | (3,264,000) | ||||||
BB yield | 2.91% | 4.37% | ||||||
| Debt | ||||||||
Debt current | 25,000 | 196,000 | ||||||
Long-term debt | 2,461,000 | 2,008,000 | ||||||
Deferred revenue | 83,000 | 673,000 | ||||||
Other long-term liabilities | 256,000 | (94,000) | ||||||
Net debt | (10,861,000) | (16,016,000) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (3,118,000) | 4,981,000 | ||||||
CAPEX | (707,000) | (400,000) | ||||||
Cash from investing activities | 4,206,000 | (5,176,000) | ||||||
Cash from financing activities | (1,377,000) | (3,448,000) | ||||||
FCF | (5,530,000) | 7,451,000 | ||||||
| Balance | ||||||||
Cash | 8,604,000 | 9,902,000 | ||||||
Long term investments | 4,743,000 | 8,318,000 | ||||||
Excess cash | 13,004,600 | 17,256,850 | ||||||
Stockholders' equity | 13,483,000 | 17,950,000 | ||||||
Invested Capital | 2,431,400 | 3,597,150 | ||||||
ROIC | 196.83% | |||||||
ROCE | 44.68% | |||||||
| EV | ||||||||
Common stock shares outstanding | 382,000 | 416,000 | ||||||
Price | 99.45 -44.63% | 179.62 -29.28% | ||||||
Market cap | 37,989,900 -49.16% | 74,721,920 -31.74% | ||||||
EV | 27,128,900 | 58,705,920 | ||||||
EBITDA | (3,618,000) | 9,768,000 | ||||||
EV/EBITDA | 6.01 | |||||||
Interest | 38,000 | 29,000 | ||||||
Interest/NOPBT | 0.31% | |||||||